Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A Post published:August 3, 2022 Post category:Press Release
COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference Post published:August 2, 2022 Post category:Press Release
Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results Post published:August 2, 2022 Post category:Press Release
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update Post published:August 2, 2022 Post category:Press Release
BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics Post published:August 1, 2022 Post category:News
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Post published:July 30, 2022 Post category:Press Release
FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE Post published:July 29, 2022 Post category:Press Release
Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing Post published:July 29, 2022 Post category:Psychedelic Bulletin
Inside the Challenge to DEA’s Proposed Scheduling of 5 Psychedelic Tryptamines Post published:July 29, 2022 Post category:Analysis/News
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa Post published:July 29, 2022 Post category:Press Release